Researchers discover how artificial intelligence can detect tumour

AI can be trained to detect whether or not a tissue picture contains a tumour. However, until recently, it has remained a mystery as to how it makes its judgement

Artificial intelligence, ai, machine learning, technology
ANI Health
3 min read Last Updated : Sep 04 2022 | 9:16 AM IST

Artificial intelligence (AI) can be trained to detect whether or not a tissue picture contains a tumour. However, until recently, it has remained a mystery as to how it makes its judgement. A team from Ruhr-Universitat Bochum's Research Center for Protein Diagnostics (PRODI) is working on a new approach that will make an AI's judgement clear and hence trustworthy.

The researchers led by Professor Axel Mosig describe the approach in the journal Medical Image Analysis.

For the study, bioinformatics scientist Axel Mosig cooperated with Professor Andrea Tannapfel, head of the Institute of Pathology, oncologist Professor Anke Reinacher-Schick from the Ruhr-Universitat's St. Josef Hospital, and biophysicist and PRODI founding director Professor Klaus Gerwert. The group developed a neural network, i.e. an AI, that can classify whether a tissue sample contains tumour or not. To this end, they fed the AI a large number of microscopic tissue images, some of which contained tumours, while others were tumour-free.

"Neural networks are initially a black box: it's unclear which identifying features a network learns from the training data," explains Axel Mosig. Unlike human experts, they lack the ability to explain their decisions. "However, for medical applications in particular, it's important that the AI is capable of explanation and thus trustworthy," adds bioinformatics scientist David Schuhmacher, who collaborated on the study.

AI is based on falsifiable hypotheses

The Bochum team's explainable AI is therefore based on the only kind of meaningful statements known to science: on falsifiable hypotheses. If a hypothesis is false, this fact must be demonstrable through an experiment. Artificial intelligence usually follows the principle of inductive reasoning: using concrete observations, i.e. the training data, the AI creates a general model on the basis of which it evaluates all further observations.

The underlying problem had been described by philosopher David Hume 250 years ago and can be easily illustrated: No matter how many white swans we observe, we could never conclude from this data that all swans are white and that no black swans exist whatsoever. Science therefore makes use of so-called deductive logic. In this approach, a general hypothesis is the starting point. For example, the hypothesis that all swans are white is falsified when a black swan is spotted.

Activation map shows where the tumour is detected

"At first glance, inductive AI and the deductive scientific method seem almost incompatible," says Stephanie Schorner, a physicist who likewise contributed to the study. But the researchers found a way. Their novel neural network not only provides a classification of whether a tissue sample contains a tumour or is tumour-free, it also generates an activation map of the microscopic tissue image.

The activation map is based on a falsifiable hypothesis, namely that the activation derived from the neural network corresponds exactly to the tumour regions in the sample. Site-specific molecular methods can be used to test this hypothesis.

"Thanks to the interdisciplinary structures at PRODI, we have the best prerequisites for incorporating the hypothesis-based approach into the development of trustworthy biomarker AI in the future, for example to be able to distinguish between certain therapy-relevant tumour subtypes," concludes Axel Mosig.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :artifical intelligencescience researchbrain tumour

First Published: Sep 04 2022 | 9:16 AM IST

Next Story